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Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of 
high energy beta-particles. The development of water-soluble polymers such as PEI-MP 
(polyethyleneimine, functionalised with methylphosphonate groups) that might be labeled with 
188Re are recent approaches, with a strong potential for metabolic radiotherapy. The aim of this 
study was to evaluate the efficacy of 188Re-PEI-MP, as therapeutic agent for bladder carcinoma.  
Material and Methods: To proceed with the in vivo studies, it was investigated the cytotoxicity of 
PEI-MP in bladder carcinoma cell line (CRL-1472) using the MTT test for different concentrations 
of PEI-MP (1 µM to 1000 µM) and incubation times (24h, 48h, 72h and 96h). Radiochemical 
purity of 188Re-PEI-MP was achieved using microchromatography. The in vivo studies were 
performed using four groups of Balb/c nu/nu mice: two normal groups injected with Na188ReO4 
(n=18) and 188Re-PEI-MP (n=17) respectively; two with bladder carcinoma xenotransplants 
injected with Na188ReO4 (n=8) and 188Re-PEI-MP (n=12) respectively. When tumor reached the 
appropriate volume, Na188ReO4 and 188Re-PEI-MP were administered by an intravenous injection 
in the tail vein (22-37MBq), with the animal anesthetized and previously placed on the gamma 
 
  
  
  
 
 
 
 
 
camera detector. Immediately, a dynamic acquisition followed, with a 128x128 matrix for 10 min 
(20 frames, 30 seconds). Static images (2 min) were performed with a 256x256 matrix, where 
each of the four groups was divided into two groups, of which one was imaged at 120 minutes, 
and the other at 240 minutes. For biodistribution proposes, mice were euthanized 2 and 4 hours 
after injection and organ samples where weighted and counted in a well-counter to obtain 
percentage injected activity per gram of organ (%ID/g).  
Results: The MTT assay showed that PEI-MP is not cytotoxic. The radiochemical purity of 188Re-
PEI-MP was ≥90%. Biodistribution results, with Na188ReO4, showed a higher uptake by the 
thyroid, bladder and stomach, following a normal biodistribution. The biodistribution with 188Re-
PEI-MP showed that the excretion of this complex occurs primarily through the renal system, with 
a small fraction being eliminated by the hepatobiliary system. Tumor/muscle ratio was greater 
than 1.5. 
Conclusions: 188Re-PEI-MP seems to be promising in the treatment of bladder cancer. 
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